TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27405101

Group type: EXPERIMENTAL
Intervention: Processed meat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole roasted pork (beheaded)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Living animal in meat advertisement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Describing industrial meat production as 'harvesting'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacing 'beef/pork' with 'cow/pig' in a restaurant menu
Number of subjects: 0
Study: 24232133

Group type: EXPERIMENTAL
Intervention: Multiple port sites training (M group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single port site training (S group)
Number of subjects: 20
Study: 23147684

Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support with twice-monthly audits and printed management suggestions based on guideline-recommended blood pressure targets
Number of subjects: 830

Group type: COMPARATOR
Intervention: Control group without audit and feedback decision support
Number of subjects: 830
Study: 20850812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19067936

Group type: EXPERIMENTAL
Intervention: School sex education
Number of subjects: 11825
Study: 16408185

Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 60
Study: 12645703

Group type: EXPERIMENTAL
Intervention: CABG (off-pump and on-pump)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CABG patients
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CABG patients with cognitive decline
Number of subjects: 81
Study: 10637462

Group type: EXPERIMENTAL
Intervention: IIEF-5 diagnostic test
Number of subjects: 1152
Study: 8606331

Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis (PA) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (CO) group
Number of subjects: 90
Study: 2082484

Group type: EXPERIMENTAL
Intervention: Aspirin, 50 mg t.i.d.
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole, 50 mg t.i.d. plus 75 mg t.i.d.
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 117967

Group type: EXPERIMENTAL
Intervention: Total muscle protein breakdown
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Percentage of total muscle protein degraded
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Protein degradation in infants losing weight
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Protein degradation in infants gaining weight
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Protein degradation in infants who died within 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Myofibrillar protein breakdown
Number of subjects: 36
Study: 30200118

Group type: EXPERIMENTAL
Intervention: Intermittent feeding with semi-solid nutrients (IS)
Number of subjects: 28
Study: 27203279

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 460

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 460
Study: 24959618

Group type: EXPERIMENTAL
Intervention: Sufentanil administration at 0.15 ng · mL(‐1) until extubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline administration (Control group)
Number of subjects: 0
Study: 22851805

Group type: EXPERIMENTAL
Intervention: SB‐649868 (10, 30, 60 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SB‐649868 (60 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20170699

Group type: EXPERIMENTAL
Intervention: Risperidone 6mg daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Olanzapine 20mg daily
Number of subjects: 94
Study: 18945282

Group type: EXPERIMENTAL
Intervention: Alcohol-based oily disinfectant gel containing 70% ethanol after regular hand washing
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Control DCCs (no alcohol-based hand-disinfection)
Number of subjects: 1431
Study: 15832830

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with 100% adherence
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with at least 80% adherence
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with < 80% adherence
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Baseline QoL scores
Number of subjects: 1050
Study: 12875727

Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group A)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 0.3 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group B)
Number of subjects: 236

Group type: COMPARATOR
Intervention: 1 tab Caltrate‐D per day (Group C)
Number of subjects: 236
Study: 10606110

Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin (1 mg/kg bolus dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 60
Study: 8542245

Group type: EXPERIMENTAL
Intervention: DTIC plus interferon
Number of subjects: 73

Group type: COMPARATOR
Intervention: DTIC alone
Number of subjects: 73
Study: 2145212

Group type: EXPERIMENTAL
Intervention: Vaccine with gamma-interferon (2 million units/m2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 81
Study: 6990474

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 91

Group type: COMPARATOR
Intervention: Pivampicillin
Number of subjects: 91
Study: 6380897

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (100 mg suppositories)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppositories)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30755574

Group type: EXPERIMENTAL
Intervention: I.V. Clonidine (2mcg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: I.V. Fentanyl (2mcg/kg)
Number of subjects: 80
Study: 30864768

Group type: EXPERIMENTAL
Intervention: ECA-Q (Embodied Conversational Agent for smoking cessation), 14-day program delivered through Tablet computers
Number of subjects: 6
Study: 25345257

Group type: EXPERIMENTAL
Intervention: Moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil (S)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream (HC)
Number of subjects: 29
Study: 22814367

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Screening tests for glucose abnormalities or CAD
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Mean systolic blood pressure
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Mean diastolic blood pressure
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Mean total cholesterol
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Percentage of patients with blood pressure below 140/90 mmHg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Percentage of patients with blood pressure below 130/80 mmHg
Number of subjects: 396
Study: 20356485

Group type: COMPARATOR
Intervention: PCM group (pantoprazole 40 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day for 7 days)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: PCM plus wenweishu group
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: PCM plus yangweishu group
Number of subjects: 642
Study: 17934599

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking stimulation using an orthodontic pacifier (Nuk)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking stimulation using a gloved finger
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no non-nutritive sucking stimulation)
Number of subjects: 95
Study: 16127252

Group type: EXPERIMENTAL
Intervention: DWI imaging
Number of subjects: 191
Study: 12693153

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study: 10446945

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 7841054

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2c monotherapy (30 micrograms m‐2 s.c. twice weekly)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Combination of rIFN‐alpha 2c and rIFN‐gamma (30 micrograms m‐2 rIFN‐alpha 2c and 100 micrograms m‐2 rIFN‐gamma)
Number of subjects: 102
Study: 2221590

Group type: EXPERIMENTAL
Intervention: Budesonide, 400 micrograms daily for 1 yr
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 32
Study: 515535

Group type: EXPERIMENTAL
Intervention: 0.02 mg of Ba 253 as metered aerosols
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2 mg of Ba 253 as metered aerosols
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31947038

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure with randomized height changes and perturbations
Number of subjects: 0
Study: 28082335

Group type: EXPERIMENTAL
Intervention: Theophylline (3.75 mg/Kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study: 25474535

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g every 6 hours for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24499497

Group type: EXPERIMENTAL
Intervention: NRL001 (5, 7.5 or 10 mg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 22964494

Group type: EXPERIMENTAL
Intervention: New-generation digital flexible ureteroscope (Invisio D-URD; distal tip diameter = 8.7 Fr)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Old-generation fibre-optic flexible ureteroscope (DUR-8; distal tip diameter = 6.75 Fr)
Number of subjects: 140
Study: 21577364

Group type: EXPERIMENTAL
Intervention: Lamotrigine (500.0 mg/d)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Topiramate (300.0 mg/d)
Number of subjects: 51
Study: 17327309

Group type: EXPERIMENTAL
Intervention: High tertile of dairy calcium intake
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Dairy calcium intake
Number of subjects: 259
Study: 15610836

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg/hr
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg/kg/hr
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 0.9 mg/kg/hr
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 1.2 mg/kg/hr
Number of subjects: 80
Study: 10746845

Group type: EXPERIMENTAL
Intervention: Estradiol vaginal tablets (EVT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Estriol vagitories (EV)
Number of subjects: 96
Study: 8958490

Group type: COMPARATOR
Intervention: bupivacaine (B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: bupivacaine with diamorphine (BD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: bupivacaine with midazolam (BM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: bupivacaine with diamorphine and midazolam (BMD)
Number of subjects: 52
Study: 8251890

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 622
Study: 3092610

Group type: EXPERIMENTAL
Intervention: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during sauna
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control day (no intervention)
Number of subjects: 12
Study: 30442276

Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3L (adult perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ‐5D‐Y (child perspective)
Number of subjects: 0

Group type: COMPARATOR
Intervention: C‐TTO responses
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCE + death valuations
Number of subjects: 0
Study: 29622823

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional care only (Control Group)
Number of subjects: 12
Study: 25668238

Group type: EXPERIMENTAL
Intervention: Clobetasol + Spironolactone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clobetasol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23266440

Group type: EXPERIMENTAL
Intervention: Group-based cognitive-behavioral weight loss program with telephone counseling and tailored newsletters
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 693
Study: 21216318

Group type: EXPERIMENTAL
Intervention: Mandatory seasonal influenza vaccine program
Number of subjects: 2443
Study: 18305062

Group type: EXPERIMENTAL
Intervention: alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks
Number of subjects: 297

Group type: COMPARATOR
Intervention: chlorambucil, 40 mg/m(2) orally every 28 days for a maximum of 12 months
Number of subjects: 297
Study: 16564618

Group type: EXPERIMENTAL
Intervention: Active motor tDCS (2mA, 20 min for 5 consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 12547477

Group type: EXPERIMENTAL
Intervention: Mirtazapine (up to 45 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 29
Study: 10711525

Group type: EXPERIMENTAL
Intervention: Generic warfarin sodium product (Barr Laboratories)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Coumadin (Dupont Pharma)
Number of subjects: 210
Study: 8992905

Group type: EXPERIMENTAL
Intervention: Oral intubation, suxamethonium (1.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral intubation, vecuronium (0.1 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal intubation, suxamethonium (1.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal intubation, vecuronium (0.1 mg/kg)
Number of subjects: 40
Study: 1347866

Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 12
Study: 3978827

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study: 30636636

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (four lifestyle counselling sessions covering a balanced healthy diet, regular physical activity and self‐monitoring of weight gain)
Number of subjects: 2286

Group type: COMPARATOR
Intervention: Control (leaflets with general recommendations for a healthy lifestyle during pregnancy)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2286

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2286
Study: 29044974

Group type: EXPERIMENTAL
Intervention: AT LISAtri 839MP (Carl Zeiss Meditec)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AT LISA 809 M (Carl Zeiss Meditec)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD1 (Alcon)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 52
Study: 26339899

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) with psychosocial support
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo with psychosocial support
Number of subjects: 101
Study: 25168524

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the posterior tibialis nerve (treatment group, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: General advice and stretching sessions (control group, n = 12)
Number of subjects: 24
Study: 23893828

Group type: EXPERIMENTAL
Intervention: SMART Arm training with OT‐stim
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SMART Arm training alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 28
Study: 20800489

Group type: EXPERIMENTAL
Intervention: Forward cane placement followed by the ipsilateral foot, then contralateral foot (FCI)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Forward cane placement followed by the contralateral foot, then ipsilateral foot (FCC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ipsilateral foot stepping up first, followed by the contralateral foot, then the cane (LCI)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Contralateral foot stepping up, followed by the ipsilateral foot, then the cane (LCC)
Number of subjects: 5

Group type: COMPARATOR
Intervention: No cane (NC)
Number of subjects: 5
Study: 18759213

Group type: EXPERIMENTAL
Intervention: Multifocal lens (ReSTOR, Alcon)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Monofocal lens (SA60AT, Alcon)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Binocular vision
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: General satisfaction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Far visual acuity satisfaction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Near visual acuity satisfaction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Use of glasses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Halos and glare
Number of subjects: 13
Study: 17083352

Group type: EXPERIMENTAL
Intervention: 40 micro g ciclesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 micro g ciclesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14660453

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 16
Study: 10999558

Group type: EXPERIMENTAL
Intervention: Ganaxolone (1500 mg/d on day 1 and 1875 mg/d on days 2 to 8, administered three times per day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 52
Study: 7938556

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAOIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective MAOI-A inhibitors (moclobemide, brofaromine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 2766 (MSH/ACTH analog)
Number of subjects: 0
Study: 3130175

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (TAM 20 mg/day orally for 2 years in postmenopausal patients; oophorectomy before TAM in premenopausal patients)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Chemotherapy (0.06 mg/kg of mitomycin C IV and 100 mg cyclophosphamide orally for 6 months repeated four times in 2 years)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (TAM with MMC + CPA chemotherapy)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Endocrine therapy (TAM)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Chemotherapy (MMC + CPA)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Chemoendocrine therapy (MMC + CPA + TAM)
Number of subjects: 692
Study: 29706760

Group type: EXPERIMENTAL
Intervention: Usual care plus intensive task-specific hand training program with functional electrical stimulation for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study: 26510663

Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 538
Study: 26819359

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (n = 11; total cumulative dose of 180 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral prednisolone (n = 10)
Number of subjects: 21
Study: 23339047

Group type: EXPERIMENTAL
Intervention: Insulin therapy (hyperinsulinaemic normoglycaemic clamp protocol)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (standard therapy with no additional dietary supplement)
Number of subjects: 56
Study: 21303456

Group type: EXPERIMENTAL
Intervention: Levine technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Z technique
Number of subjects: 50
Study: 19446909

Group type: EXPERIMENTAL
Intervention: VCH-759 400mg t.i.d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: VCH-759 800mg b.i.d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: VCH-759 800mg t.i.d.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17277349

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day, or rosuvastatin 20-40 mg/day)
Number of subjects: 110271
Study: 14560320

Group type: EXPERIMENTAL
Intervention: Oral THC (0, 10 mg) administered five times/day during marijuana abstinence (days 9-14)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Divalproex (0, 1500 mg/day) maintained for 29 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo THC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo marijuana
Number of subjects: 14
Study: 11296186

Group type: EXPERIMENTAL
Intervention: Intermittent dobutamine infusion (IDI), 10 micromin, as needed (mean, once every 16 days, lasting for 12 to 48 h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral amiodarone, 400 mg/d, and IDI, 10 microg/kg/min, for 8 h every 7 days
Number of subjects: 22
Study: 9632900

Group type: EXPERIMENTAL
Intervention: salbutamol (Sb) 200 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ipratropium bromide (IB) 200 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo (freon propellant)
Number of subjects: 15
Study: 10151166

Group type: EXPERIMENTAL
Intervention: Single house call by a health visitor 72 hours after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal post-discharge care (Control)
Number of subjects: 0
Study: 2235007

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Betaxolol eyedrops
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carteolol eyedrops
Number of subjects: 40